Table 8:
Adverse Outcomes After TAVI or SAVR in PARTNER Trial, Cohort A, Intention-to-Treat Analysisa
| Author, Year | All-Cause Mortality, N (%) | Cardiovascular Mortality, N (%) | Aortic Regurgitation, N (%) | Stroke, N (%) | Vascular Complications, N (%) | Major Bleeding, N (%) | New Pacemaker, N (%) | Myocardial Infarction, N (%) | Renal Failure, N (%) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Paravalvular | Transvalvular | |||||||||
|
30 days Smith et al, 201120 |
TAVI: 12 (3.4) SAVR: 22 (6.5) P = .07 |
TAVI: 11 (3.2) SAVR: 10 (3.0) P = .90 |
Moderate/severe TAVI: 35/287 (12.2) SAVR: 2/229 (0.9) Mild TAVI: 187/287 (65.2) SAVR: 58/229 (25.3) |
Moderate/severe TAVI: 3/291 (0.1) SAVR: 2/230 (0.9) Mild TAVI: 185/291 (63.6) SAVR: 100/230 (43.2) |
Major TAVI: 13 (3.8) SAVR: 7 (2.1) P = .20 Minor TAVI: 3 (0.9) SAVR: 1 (0.3) P = .34 |
All TAVI: 59 (17) SAVR: 13 (3.8) P < .001 Major TAVI: 38 (11.0) SAVR: 11 (3.2) P < .001 |
TAVI: 32 (9.3) SAVR: 67 (19.5) P < .001 |
TAVI: 13 (3.8) SAVR: 12 (3.6) P = .89 |
TAVI: 0 (0) SAVR: 2 (0.6) P = .16 |
TAVI: 10 (2.9) SAVR: 10 (3.0) P = .95 |
|
1 year Smith et al, 201120 |
TAVI: 84 (24.2) SAVR: 89 (26.8) P = .44 |
TAVI: 47 (14.3) SAVR: 40 (13) P = .63 |
Moderate/severe TAVI: 15/222 (6.8) SAVR: 3/159 (1.9) P < .001 Mild TAVI: 134/222 (60.4) SAVR: 32/159 (20.1) |
Moderate/severe TAVI: 2/225 (0.9) SAVR: 0/159 (0) Mild TAVI: 141/225 (62.7) SAVR: 71/159 (44.7) |
Major TAVI: 17 (5.1) SAVR: 8 (2.4) P = .07 Minor TAVI: 3 (0.9) SAVR: 2 (0.7) P = .84 |
All TAVI: 62 (18) SAVR: 16 (4.8) P < .001 Major TAVI: 39 (11.3) SAVR: 12 (3.5) P < .001 |
TAVI: 49 (14.7) SAVR: 85 (25.7) P < .001 |
TAVI: 19 (5.7) SAVR: 16 (5.0) P = .68 |
TAVI: 1 (0.4) SAVR: 2 (0.6) P = .69 |
TAVI: 18 (5.4) SAVR: 20 (6.5) P = .56 |
|
2 years Kodali et al, 201212 Miller et al, 201229 |
TAVI: 116 (33.9) SAVR: 114 (35) P = .78 |
TAVI: 67 (21.4) SAVR: 59 (20.5) P = .8 |
Moderate/severe TAVI: (6.9) SAVR: (0.9) P < .001 Mild TAVI: (38.6) SAVR: (6.3) |
NA |
Major TAVI: 18 (5.2) SAVR: 10 (2.8) Minor TAVI: 5 (1.5) SAVR: 1 (0.3) |
TAVI: 40 (11.6) SAVR: 13 (3.8) P < .001 |
TAVI: 60 (19.0) SAVR: 95 (29.5) P = .002 |
TAVI: 23 (7.2) SAVR: 19 (6.4) P = .69 |
TAVI: 0 (0) SAVR: 4 (1.5) P = .05 |
TAVI: 20 (6.2) SAVR: 21 (6.9) P = .75 |
|
5 years Mack et al, 201532 |
TAVI: 229 (67.8) SAVR: 198 (62.4) P = .76 |
TAVI: 147 (53.1) SAVR: 123 (47.6) P = .67 |
TAVI: 85/100 (85.0) SAVR: 79/97 (81.4) |
Moderate/severe TAVI: 2/280 (0.7) SAVR: 1/228 (0.4) Mild NA |
TAVI: 29 (10.4) SAVR: 26 (11.3) P = .61 |
TAVI: 41 (11.9) SAVR: 14 (4.7) P = .0002 |
TAVI: 75 (26.6) SAVR: 103 (34.4) P = .003 |
TAVI: 28 (9.7) SAVR: 23 (9.1) P = .64 |
TAVI: 5 (2.9) SAVR: 11 (5.9) P = .15 |
TAVI: 24 (8.6) SAVR: 24 (8.5) P = .69 |
Abbreviations: NA, not available; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.
a
Percentages are based on Kaplan-Meier estimates as reported by the authors and do not equal the number of patients with events divided by the total number of patients.